Bertlich, Mattis

[["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Kruizenga, Marie"],["dc.contributor.author","Freytag, Saskia"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Haubner, Frank"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Weiss, Bernhard G."],["dc.date.accessioned","2021-04-14T08:32:11Z"],["dc.date.available","2021-04-14T08:32:11Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00405-020-06389-7"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83839"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1434-4726"],["dc.relation.issn","0937-4477"],["dc.title","Cancer stem cell markers in adenocarcinoma of the salivary glands - reliable prognostic markers?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","648"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","654"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Bettag, Stephan A."],["dc.contributor.author","Desinger, Hendrik"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2017"],["dc.description.abstract","Objective: Disturbance of cochlear microcirculation is considered to be the final common pathway of various inner ear diseases. Hyperfibrinogenemia causing increased plasma viscosity is a known risk factor for sudden sensorineural hearing loss and may lead to a critical reduction of cochlear blood flow. The aim of this study was to evaluate the effect of a substantial reduction of plasma fibrinogen levels by drug-induced defibrinogenation for the treatment of acute hearing loss in vivo. Methods: Acute hearing loss was induced by hyperfibrinogenemia (i.v. injection of 330 mg/kg BW fibrinogen), using a guinea pig animal model. Parameters of cochlear microcirculation and hearing thresholds were quantified by intravital microscopy and evoked response audiometry. After obtaining baseline values, the course of hearing loss and disturbances of microcirculation were investigated under influence of intravenous defibrinogenation therapy (ancrod), corticosteroid, or placebo treatment, using 5 animals/group. Results: Acute hyperfibrinogenemia caused hearing loss from 10 +/- 7 to 26 +/- 10 dB SPL at baseline. Drug-induced reduction of fibrinogen levels showed a significant increase of cochlear microcirculation (1.6-fold) and recovered hearing threshold (11 +/- 6 dB SPL). Placebo or corticosteroid treatment had no effect on hearing loss (35 +/- 7 dB SPL and 32 +/- 18 dB SPL, respectively). Conclusion: Acute hyperfibrinogenemia resulted in hearing loss. Drug-induced reduction of elevated fibrinogen levels caused an increase in cochlear blood flow and a decrease in hearing thresholds. Placebo or corticosteroid treatment had no effect. Reduction of plasma fibrinogen levels could serve as a clinical treatment option for acute hearing loss."],["dc.identifier.doi","10.1097/MAO.0000000000001400"],["dc.identifier.isi","000401025800004"],["dc.identifier.issn","1531-7129"],["dc.identifier.pmid","28369007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75431"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1537-4505"],["dc.relation.issn","1531-7129"],["dc.title","Drug-induced Defibrinogenation as New Treatment Approach of Acute Hearing Loss in an Animal Model for Inner Ear Vascular Impairment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1213"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","1216"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Freytag, Saskia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Strupp, Michael"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1097/MAO.0000000000001510"],["dc.identifier.issn","1531-7129"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75432"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","753"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Audiology"],["dc.bibliographiccitation.lastpage","759"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Ihler, Fritz"],["dc.contributor.author","Sharaf, Kariem"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Strupp, Michael"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:34:52Z"],["dc.date.available","2018-11-07T09:34:52Z"],["dc.date.issued","2014"],["dc.description.abstract","Objective: Betahistine is a histamine-like drug that is used in the treatment of Meniere's disease. It is commonly believed that betahistine increases cochlear blood flow and thus decreases the endolymphatic hydrops that is the cause of Meniere's. Despite common clinical use, there is little understanding of the kinetics or effects of its metabolites. This study investigated the effect of the betahistine metabolites aminoethylpyridine, hydroxyethylpyridine, and pyridylacetic acid on cochlear microcirculation. Design: Guinea pigs were randomly assigned to one of the groups: placebo, betahistine, or equimolar amounts of aminoethylpyridine, hydroxyethylpyridine, or pyridylacetic acid. Cochlear blood flow and mean arterial pressure were recorded for three minutes before and 15 minutes after treatment. Study sample: Thirty Dunkin-Hartley guinea pigs assigned to one of five groups with six guinea pigs per group. Results: Betahistine, aminoethylpyridine, and hydroxyethylpyridine caused a significant increase in cochlear blood flow in comparison to placebo. The effect seen under aminoethylpyridin was greatest. The group treated with pyridylacetic acid showed no significant effect on cochlear blood flow. Conclusion: Aminoethylpyridine and hydroxyethylpyridine are, like betahistine, able to increase cochlear blood flow significantly. The effect of aminoethylpyridine was greatest. Pyridylacetic acid had no effect on cochlear microcirculation."],["dc.identifier.doi","10.3109/14992027.2014.917208"],["dc.identifier.isi","000341928600008"],["dc.identifier.pmid","25014609"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32270"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1708-8186"],["dc.relation.issn","1499-2027"],["dc.title","Betahistine metabolites, Aminoethylpyridine, and Hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3001"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","3009"],["dc.bibliographiccitation.volume","274"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Scheele, Rebecka"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Sohns, Jan M."],["dc.contributor.author","Ihler, Friedrich"],["dc.date.accessioned","2020-12-10T14:10:29Z"],["dc.date.available","2020-12-10T14:10:29Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00405-017-4609-5"],["dc.identifier.eissn","1434-4726"],["dc.identifier.issn","0937-4477"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70775"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Systematic radiographic evaluation of three potential implantation sites for a semi-implantable bone conduction device in 52 patients after previous mastoid surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","468"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Otology Rhinology & Laryngology"],["dc.bibliographiccitation.lastpage","473"],["dc.bibliographiccitation.volume","122"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Sharaf, Kariem"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Strieth, Sebastian"],["dc.contributor.author","Reichel, Christoph A."],["dc.contributor.author","Berghaus, Alexander"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:22:58Z"],["dc.date.available","2018-11-07T09:22:58Z"],["dc.date.issued","2013"],["dc.description.abstract","Objectives: Tumor necrosis factor alpha (TNF-alpha) is a mediator of inflammation and microcirculation in the cochlea. This study aimed to quantify the effect of a local increase of TNF-alpha and study the effect of its interaction with etanercept on cochlear microcirculation. Methods: Cochlear lateral wall vessels were exposed surgically and assessed by intravital microscopy in guinea pigs in vivo. First, 24 animals were randomly distributed into 4 groups of 6 each. Exposed vessels were superfused repeatedly either with 1 of 3 different concentrations of TNF-alpha (5.0, 0.5, and 0.05 ng/mL) or with placebo (0.9% saline solution). Second, 12 animals were randomly distributed into 2 groups of 6 each. Vessels were pretreated with etanercept (1.0 mu g/mL) or placebo (0.9% saline solution), and then treated by repeated superfusion with TNF-alpha (5.0 ng/mL). Results: TNF-alpha was shown to be effective in decreasing cochlear blood flow at a dose of 5.0 ng/mL (p < 0.01, analysis of variance on ranks). Lower concentrations or placebo treatment did not lead to significant changes. After pretreatment with etanercept, TNF-alpha at a dose of 5.0 ng/mL no longer led to a change in cochlear blood flow. Conclusions: The decreasing effect that TNF-alpha has on cochlear blood flow is dose-dependent. Etanercept abrogates this effect."],["dc.identifier.isi","000321880700011"],["dc.identifier.pmid","23951701"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29467"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Annals Publ Co"],["dc.relation.issn","0003-4894"],["dc.title","Etanercept Prevents Decrease of Cochlear Blood Flow Dose-Dependently Caused by Tumor Necrosis Factor Alpha"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Anczykowski, Mahalia Zoe"],["dc.contributor.author","Küffer, Stefan"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Jakob, Mark"],["dc.date.accessioned","2021-04-14T08:24:45Z"],["dc.date.available","2021-04-14T08:24:45Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00405-020-06262-7"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81414"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1434-4726"],["dc.relation.issn","0937-4477"],["dc.title","Prognostic impact of additional HPV diagnostics in 102 patients with p16-stratified advanced oropharyngeal squamous cell carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e5"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","e11"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Söchting, Friederike"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Busch, Martin"],["dc.contributor.author","Blum, Jenny"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1097/MAO.0000000000001611"],["dc.identifier.issn","1531-7129"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75434"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An Objective Method to Determine the Electrically Evoked Stapedius Reflex Threshold During Cochlea Implantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E203"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","E208"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Sharaf, Kariem"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Reichel, Christoph A."],["dc.contributor.author","Berghaus, Alexander"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:56Z"],["dc.date.available","2020-12-10T18:19:56Z"],["dc.date.issued","2016"],["dc.description.abstract","Hypothesis: This study aimed to quantify the effects of tumor necrosis factor (TNF) inhibitor Etanercept and sphin-gosine-1-phosphate receptor 2 antagonist JTE-013 on cochlear blood flow in guinea pigs after TNF-induced decrease. Background: Sudden sensorineural hearing loss is a common cause for disability and reduced quality of life. Good understanding of the pathophysiology and strong evidence-based therapy concepts are still missing. In various inner ear disorders, inflammation and impairment of cochlear blood flow (CBF) have been considered factors in the pathophysiology. A central mediator of inflammation and microcirculation in the cochlea is TNF. S1P acts downstream in one TNF pathway. Methods: Cochlea lateral wall vessels were exposed surgically and assessed by intravital microscopy in guinea pigs in vivo. Twenty-eight animals were randomly distributed into four groups of seven each. Exposed vessels were superfused by TNF (5.0 ng/ml) and afterward repeatedly either by Etanercept (1.0mg/ml), JTE-013 (10mmol/L), or vehicle (0.9 % NaCl solution or ethanol: phosphate-buffered saline buffer, respectively). Results: After decreasing CBF with TNF (p<0.001, twoway RM ANOVA), both treatments reversed CBF, compared with vehicle (p<0.001, two-way RM ANOVA). The comparison of the vehicle groups showed no difference (p = 0.969, two-way RM ANOVA), while there was also no difference between the treatment groups (p = 0.850, two-way RM ANOVA). Conclusion: Both Etanercept and JTE-013 reverse the decreasing effect of TNF on cochlear blood flow and, therefore, TNF and the S1P-signalling pathway might be targets for treatment of microcirculation-related hearing loss."],["dc.identifier.doi","10.1097/MAO.0000000000001095"],["dc.identifier.isi","000380621200002"],["dc.identifier.issn","1531-7129"],["dc.identifier.pmid","27295443"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75430"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1537-4505"],["dc.relation.issn","1531-7129"],["dc.title","Tumor Necrosis Factor-induced Decrease of Cochlear Blood Flow Can Be Reversed by Etanercept or JTE-013"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1166"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK"],["dc.bibliographiccitation.lastpage","1176"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.date.accessioned","2018-11-07T10:23:26Z"],["dc.date.available","2018-11-07T10:23:26Z"],["dc.date.issued","2017"],["dc.description.abstract","Background. Surgical treatment options for local recurrences of laryngeal cancer can be either organ-preserving surgery or total laryngectomy. The purpose of this study was to present our evaluation of the treatment with transoral laser microsurgery (TLM) in comparison to laryngectomy. Methods. We conducted a retrospective review of 199 consecutive patients with recurrent laryngeal cancer at 1 tertiary referral center. Results. The 5-year overall survival, disease-specific survival, and local control rates were 64.8%, 79.6%, and 57.5%, respectively, for 93 patients with early tumors treated by TLM, 28.9%, 41.7%, and 43.7%, respectively, for 52 patients with advanced tumors treated by TLM as well as 39.4%, 44.6%, and 68.8%, respectively, for 54 patients with advanced tumors treated by total laryngectomy. Five-year larynx-preservation rate was 77.7% for early as well as 68.4% for advanced tumors treated by TLM. Conclusion. TLM is an option in early and in selected cases of advanced locally recurrent laryngeal cancer. (C) 2017 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/hed.24737"],["dc.identifier.isi","000401269000015"],["dc.identifier.pmid","28252821"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42453"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.relation.issn","1097-0347"],["dc.relation.issn","1043-3074"],["dc.title","Transoral laser microsurgery or total laryngectomy for recurrent squamous cell carcinoma of the larynx: Retrospective analysis of 199 cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]